---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-280283"
form_type: "8-K"
ticker: "INAB"
cik: "0001740279"
company_name: "IN8BIO, INC."
filed_at: "2023-11-20T23:59:59+00:00"
generated_at: "2026-06-07T23:26:11.945335+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# IN8bio's INB-200 Phase 1 trial: all patients completing doses exceed 7-month PFS; one remains alive at 28.5+ months

## Summary
- All ten patients who completed mandated doses exceeded progression-free survival (PFS) of 7 months, exceeding standard-of-care median PFS of 4-7 months.
- One patient with IDH-mutant glioma remains alive and progression-free at 28.5+ months (median PFS for IDH-mutant patients in NEJM control arm: 11.1 months).
- No treatment-related serious adverse events, dose-limiting toxicities, cytokine release syndrome, infusion reactions, or ICANS reported.
- Three dosing cohorts: Cohort 1 (1 dose, 3 pts), Cohort 2 (3 doses, 4 pts), Cohort 3 (6 doses, 3 pts); additional enrollment in Cohort 3 expected to complete in 2023.
- Preserved gamma-delta T cells found in relapsed tumor 148 days after initial DRI infusion, indicating durability of cells.

## SEC filing metadata
- accession: 0001193125-23-280283
- form_type: 8-K
- ticker: INAB
- cik: 0001740279
- company_name: IN8BIO, INC.
- filed_at: 2023-11-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1740279/000119312523280283/0001193125-23-280283-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1740279/000119312523280283/d900996d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-280283
- JSON: https://secwatch.observer/filing/0001193125-23-280283.json
- Plain text: https://secwatch.observer/filing/0001193125-23-280283.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.